527 related articles for article (PubMed ID: 27034234)
21. Combined treatment with anti-HER2/neu and anti-4-1BB monoclonal antibodies induces a synergistic antitumor effect but requires dose optimization to maintain immune memory for protection from lethal rechallenge.
Kim HY; Choi JH; Haque MM; Park JH; Kim IH; Choi BK; Lee A; Park S
Cancer Immunol Immunother; 2022 Apr; 71(4):967-978. PubMed ID: 34988585
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy.
Kim YH; Choi BK; Oh HS; Kang WJ; Mittler RS; Kwon BS
Mol Cancer Ther; 2009 Feb; 8(2):469-78. PubMed ID: 19190115
[TBL] [Abstract][Full Text] [Related]
23. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.
Quetglas JI; Dubrot J; Bezunartea J; Sanmamed MF; Hervas-Stubbs S; Smerdou C; Melero I
Mol Ther; 2012 Sep; 20(9):1664-75. PubMed ID: 22735380
[TBL] [Abstract][Full Text] [Related]
25. Improvement of daratumumab- or elotuzumab-mediated NK cell activity by the bi-specific 4-1BB agonist, DARPin α-FAPx4-1BB: A preclinical study in multiple myeloma.
Saltarella I; Link A; Lamanuzzi A; Reichen C; Robinson J; Altamura C; Melaccio A; Solimando AG; Ria R; Mariggiò MA; Vacca A; Frassanito MA; Desaphy JF
Biomed Pharmacother; 2024 Jul; 176():116877. PubMed ID: 38850654
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.
Houot R; Goldstein MJ; Kohrt HE; Myklebust JH; Alizadeh AA; Lin JT; Irish JM; Torchia JA; Kolstad A; Chen L; Levy R
Blood; 2009 Oct; 114(16):3431-8. PubMed ID: 19641184
[TBL] [Abstract][Full Text] [Related]
27. Agonist antibodies to TNFR molecules that costimulate T and NK cells.
Melero I; Hirschhorn-Cymerman D; Morales-Kastresana A; Sanmamed MF; Wolchok JD
Clin Cancer Res; 2013 Mar; 19(5):1044-53. PubMed ID: 23460535
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.
Nakajima F; Khanna A; Xu G; Lagman M; Haschemeyer R; Mouradian J; Wang JC; Stenzel KH; Rubin AL; Suthanthiran M
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7889-93. PubMed ID: 8058730
[TBL] [Abstract][Full Text] [Related]
29. The therapeutic potential of 4-1BB (CD137) in cancer.
Nam KO; Kang WJ; Kwon BS; Kim SJ; Lee HW
Curr Cancer Drug Targets; 2005 Aug; 5(5):357-63. PubMed ID: 16101383
[TBL] [Abstract][Full Text] [Related]
30. ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.
Enell Smith K; Fritzell S; Nilsson A; Barchan K; Rosén A; Schultz L; Varas L; Säll A; Rose N; Håkansson M; von Schantz L; Ellmark P
Cancer Immunol Immunother; 2023 Dec; 72(12):4145-4159. PubMed ID: 37796298
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma.
McKee SJ; Doff BL; Soon MS; Mattarollo SR
Cancer Immunol Res; 2017 Mar; 5(3):191-197. PubMed ID: 28115358
[TBL] [Abstract][Full Text] [Related]
32. Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab.
Yonezawa A; Chester C; Rajasekaran N; Kohrt HE
Chin Clin Oncol; 2016 Feb; 5(1):5. PubMed ID: 26932429
[No Abstract] [Full Text] [Related]
33. BT7480, a novel fully synthetic
Hurov K; Lahdenranta J; Upadhyaya P; Haines E; Cohen H; Repash E; Kanakia D; Ma J; Kristensson J; You F; Campbell C; Witty D; Kelly M; Blakemore S; Jeffrey P; McDonnell K; Brandish P; Keen N
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34725211
[TBL] [Abstract][Full Text] [Related]
34. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model.
Belcaid Z; Phallen JA; Zeng J; See AP; Mathios D; Gottschalk C; Nicholas S; Kellett M; Ruzevick J; Jackson C; Albesiano E; Durham NM; Ye X; Tran PT; Tyler B; Wong JW; Brem H; Pardoll DM; Drake CG; Lim M
PLoS One; 2014; 9(7):e101764. PubMed ID: 25013914
[TBL] [Abstract][Full Text] [Related]
35. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
[TBL] [Abstract][Full Text] [Related]
36. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
Woroniecka KI; Rhodin KE; Dechant C; Cui X; Chongsathidkiet P; Wilkinson D; Waibl-Polania J; Sanchez-Perez L; Fecci PE
Clin Cancer Res; 2020 Mar; 26(6):1349-1358. PubMed ID: 31871298
[TBL] [Abstract][Full Text] [Related]
37. Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?
Weigelin B; Bolaños E; Rodriguez-Ruiz ME; Martinez-Forero I; Friedl P; Melero I
Cancer Immunol Immunother; 2016 May; 65(5):493-7. PubMed ID: 26970765
[TBL] [Abstract][Full Text] [Related]
38. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
39. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes.
Ju SA; Lee SC; Kwon TH; Heo SK; Park SM; Paek HN; Suh JH; Cho HR; Kwon B; Kwon BS; Kim BS
Immunol Cell Biol; 2005 Aug; 83(4):344-51. PubMed ID: 16033529
[TBL] [Abstract][Full Text] [Related]
40. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
